Labetuzumab is a monoclonal antibody that targets the CD20 antigen, primarily found on the surface of B cells. It is designed for therapeutic applications, particularly in the treatment of certain types of cancers, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. The mechanism of action involves binding to the CD20 antigen, which can lead to the destruction of B cells through various immune-mediated processes, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Labetuzumab is characterized by its specificity for the CD20 antigen, which makes it a valuable tool in targeted cancer therapies. As a biologic agent, it is produced through recombinant DNA technology and typically administered via intravenous infusion. The pharmacokinetics of labetuzumab can vary based on factors such as dosage and patient characteristics, and it may be associated with side effects common to monoclonal antibodies, including infusion reactions and immunosuppression. Overall, labetuzumab represents a significant advancement in the field of targeted cancer treatment.

Labetuzumab

219649-07-7: Labetuzumab is a monoclonal antibody that targets the CD20 antigen, primarily found on the surface of B cells. It is designed for therapeutic applications, particularly in the treatment of certain types of cancers, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. The mechanism of action involves binding to the CD20 antigen, which can lead to the destruction of B cells through various immune-mediated processes, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Labetuzumab is characterized by its specificity for the CD20 antigen, which makes it a valuable tool in targeted cancer therapies. As a biologic agent, it is produced through recombinant DNA technology and typically administered via intravenous infusion. The pharmacokinetics of labetuzumab can vary based on factors such as dosage and patient characteristics, and it may be associated with side effects common to monoclonal antibodies, including infusion reactions and immunosuppression. Overall, labetuzumab represents a significant advancement in the field of targeted cancer treatment.

<p>Labetuzumab (hMN-14) is an anti-carcinoembryonic antigen (CEA) monoclonal antibody with anticancer activity for the study of thyroid and colorectal cancer .</p>

<p>Anti-Human CEA Monoclonal Antibody</p>

CAS 219649-07-7

Labetuzumab

Labetuzumab

Ref: TM-T9901A-004

Labetuzumab

Ref: 3D-CLA1068